About Adela
Adela is a Healthcare company based in San Francisco (United States) founded in 2021 by Manish Agarwal, Ishank Gupta, Daniel De Carvalho, and Scott Bratman. It operates as a cancer detection platform via blood-based methylation analysis is developed. Adela has raised $133.97 million across 4 funding rounds from investors including LabCorp, Orbimed and RA Capital. Adela offers products and services including MRD Blood Test, Immunotherapy Monitoring Test, and Early Cancer Screening Test. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is Adela, Inc. Its competitors include Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Adela was founded in 2021 in San Francisco, United States, within the biotechnology sector. A platform utilizing genome-wide methylation analysis technology is provided for early cancer detection. Blood tests are developed to identify kidney cancer and intracranial brain tumors by distinguishing informative methylated genomic regions from non-informative ones, targeting specific areas for sequencing. Operations focus on advancing diagnostic tools for oncology applications.
- Headquarters San Francisco, United States
- Founders Manish Agarwal, Ishank Gupta, Daniel De Carvalho, Scott Bratman
- SectorsHealthcare
- Email••••••••
- Website adelabio.com
- Legal Name Adela, Inc.
- Total Equity Funding$133.97M (USD)
in 4 rounds
- InvestorsLabCorp
& 6 more
Products & Services of Adela
Adela offers a comprehensive portfolio of products and services, including MRD Blood Test, Immunotherapy Monitoring Test, and Early Cancer Screening Test.
Detects minimal residual disease post-surgery for recurrence monitoring.
Assesses responses to immunotherapy in cancer patients.
Identifies multiple cancer types through blood analysis for early detection.
Funding Insights of Adela
Adela has successfully raised a total of $133.97M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $133.97M
- Total Rounds 4
- First Round $60M
(Jun 2021)
- Investors Count 7
All 4 funding rounds of Adela with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | $5M | Series A | – | – | – |
| Jun 2025 | $25.43M | Series A | – | – | – |
| Jul 2023 | $48.54M | Series A | – | LabCorp, Deerfield Management Group | |
| Jun 2021 | $60M | Series A | – | F-Prime Capital |
7 investors in total: 7 institutional.
Investors in Adela
Adela has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include LabCorp, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | – | fprimecapital.com | - | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm focused on life science and technology sectors | – | decheng.com | Shanghai, China | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
Provider of laboratory tests for physicians | 1969 | labcorp.com | Burlington, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Real estate services are provided by Deerfield Management Group. | – | deerfieldmg.com | Pittsburgh, United States |
Investor details for Adela
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adela
41 people are tracked at Adela (18 in leadership, 11 in board & advisors, 12 in team).
| Name | Role | Group |
|---|---|---|
Manish Agarwal | Co-Founder | Leadership |
Ishank Gupta | Co-Founder | Leadership |
Daniel De Carvalho | Co-Founder & CSO | Leadership |
Scott Bratman | Co-Founder | Leadership |
Betsey Rapp | VP, Commercial | Leadership |
Mary T. | Sr. HR Business Partner | Leadership |
Anne-Renee Hartman | Chief Medical Officer | Leadership |
Alan Williams | COO | Leadership |
Ben Brown | Director Biostatistics | Leadership |
Kaustubh Gokhale | Associate Director | Leadership |
Stephanie H. | VP Of Product And Program Management | Leadership |
Brian Allen | Vice President, Clinical Development | Leadership |
Eduardo Sosa | Senior Director Clincical Data Management | Leadership |
Michelle Anderson | Director Of Clinical Operations | Leadership |
Jason Orck | Sr. Director Of Laboratory Operations | Leadership |
Abel L. | Vice President, Data Science And Bioinformatics | Leadership |
Hestia Mellert | Vice President Of Product Development | Leadership |
Shu Yi Shen | Director R&d Laboratory Operations | Leadership |
Gary Bader | Scientific Advisor | Board & advisors |
Sylvia K. Plevritis | Scientific Advisor | Board & advisors |
21 more people are available in the full profile.
Complete people profiles for Adela
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Adela
3 dated milestones of Adela across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Adela is founded.
- Funding First funding round of $60.0M.
- Funding Latest funding round, Series A,.
Competitors of Adela
Adela has 9 listed competitors in our database, 9 of them funded. They include Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. |
Detailed competitors of Adela
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Adela
The website of Adela (adelabio.com) receives about 7K visits a month.
- Monthly visits7K
▲ 45.5% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Adela (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adela
Complete news archive for Adela
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adela
Adela was founded in 2021.
Adela is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Adela is a funded company, having raised a total of $133.97M across 4 funding rounds to date. The company's 1st funding round was a Series A of $60M, raised on Jun 2021.
Adela was founded in 2021 in San Francisco, United States, within the biotechnology sector. A platform utilizing genome-wide methylation analysis technology is provided for early cancer detection. Blood tests are developed to identify kidney cancer and intracranial brain tumors by distinguishing informative methylated genomic regions from non-informative ones, targeting specific areas for sequencing. Operations focus on advancing diagnostic tools for oncology applications.
Adela's top competitors include Guardant Health, Juno Therapeutics and Foundation Medicine.
Adela offers MRD Blood Test, Immunotherapy Monitoring Test, and Early Cancer Screening Test.
Adela has 7 investors. Key investors include LabCorp, Orbimed, RA Capital, F-Prime Capital, and Deerfield Management Group.
Adela operates through Adela, Inc..